Transcript Protein and Amino Acid Supplements

Landscape Study Protein and Amino Acid Nutraceutical
IIPRD
An ISO 9001:2015 Certified Firm
E-13, UPSIDC, Site-IV, Kasna Road, Greater Noida, National Capital Region - 201308, India
Phone: +91.120.2342010, 3104849, Fax: 2342011 Website: www.iiprd.com
Email: [email protected]
© IIPRD, 2016
Introduction
© IIPRD, 2016
2
Introduction
• Protein is one powerful nutrient. It is part of every living cell, and plays a major
role in our body — from building our body tissues to making important
hormones. An adequate protein intake in the diet is important across the life
cycle, especially as we age.
• Amino acids (AA) are the building blocks of protein. There are 22 different amino
acids required by the body. These amino acids join together to make all different
kinds of protein. Apart from protein biosynthesis, amino acid also act as precursor
for many other biomolecules. Nine amino acids which are considered essential
amino acids are not made by the body and therefore obtained from food. The
other amino acids are synthesized by the body and thus are considered
nonessential amino acids.
• The proteins in our bodies are constantly broken down and replaced. The body
does not store amino acids like it stores carbohydrates and fats, so a daily supply
of amino acids is required to make new proteins. The protein in the foods we eat
is digested into amino acids that can be used to replace the proteins in our
bodies.
© IIPRD, 2016
3
Introduction
• Most official nutrition organizations recommend a fairly modest protein intake.
The DRI (Dietary Reference Intake) is 0.8 grams of protein per kilogram of body
weight, or 0.36 grams per pound.
• The protein requirement is based on several parameter(s) for e.g., whole-body
protein mass, muscle mass, physical function, immune function, or metabolic
function. Additionally, the protein requirement depends on quality—that is AA
composition and digestibility—and physical activity level.
• It is more important than ever to be able to describe appropriately the protein
and amino acids supplied by food/diets. The match between dietary supply and
human protein and amino acid needs is imperative to support the health and
well-being of human populations.
• Most people get enough protein. But in certain cases requirement of
protein/amino acid is much higher compared to normal individual. Protein
supplements are used to provide protein that may otherwise not be consumed in
sufficient quantities.
© IIPRD, 2016
4
Introduction
• Protein supplements are available in form of powder, tablet, jelly, drink,
beverages etc. Protein powder dominates protein products and growing rapidly.
These supplements are used to address problems associated with heart health,
diabetes, weight management, digestion, ageing etc.
• Global protein and amino acids market is estimated to grow CAGR of more than
6% by 2020.1
• Major factors driving growth of protein nutraceutical includes: increased health
awareness, omnipresent fitness and health maintenance trend, focus on leading
active lifestyles and increased participation in sports and fitness activities as
measured by higher enrollment in gyms and sports clubs. Further, protein is one
of the most marketing claim for the sale of product.
• In 2014, North America accounted for the largest share in the protein ingredients,
owing to the high consumption of protein-based products. The global market in
the Asia-Pacific region is emerging with substantial opportunities.2
© IIPRD, 2016
5
Introduction
The top health benefit of protein from consumer point of view is summarized in the
table below.1
Health Benefit
% Consumer
General Health
84
To keep Active and Agile
81
Muscle maintenance
73
Muscle recovery
71
Kids to grow
68
Strong bones
67
Sports performance
64
Weight management
58
Supress hunger
44
© IIPRD, 2016
6
Bibliographic Analysis
© IIPRD, 2016
7
Geographical Origin of Innovation
70
60
58
57
No. of Patent Families
50
40
30
20
9
10
6
6
4
3
2
2
WIPO
Italy
Belgium
Japan
0
China
USA
Europe
France
Other
Priority Country
Analysis of priority country indicates that maximum number of innovations originated from
China (58 patent families) followed by USA (57 Patent Families). Economical growth in China
attributes for the Chinese firms filing more patent in protein and amino acid based
nutraceutical sector.
© IIPRD, 2016
8
IPC Class Distribution (1/3)
Analysis of IPC Class indicates that 85 Patent families have IPC Class A23L (Foods, foodstuffs,
or non-alcoholic beverages), followed by 51 Patent Families having A61K (Preparations for
medical, dental, or toilet purposes).
© IIPRD, 2016
9
IPC Class Distribution (2/3)
60
51
No. of Patent Families
50
40
30
24
18
20
9
10
8
4
4
4
3
2
2
2
1
0
No. of Patent Families
A23L A23L
33/00 1/00
A23L
7/00
A23L A23L A23L A23L A23L A23L A23L A23L
2/00 19/00 29/00 17/00 13/00 25/00 11/00 5/00
IPC Class
40
30
31
19
20
10
A23L A23L
3/00 15/00
11
4
0
0
0
2005
2006
2007
3
4
5
3
2
2008
2009
2010
2011
2012
3
0
<2005
2013
2014
2015
2016
Year
• For the IPC Class A23L, 2015 has maximum number of patent filing followed by 2014.
• Sub Classes 33/00 (Modifying nutritive qualities of foods; dietetic products; preparation
or treatment thereof) and 1/00 (Foods or foodstuffs; their preparation or treatment)
have maximum focus.
© IIPRD, 2016
10
IPC Class Distribution (2/3)
35
31
No. of Patent Families
30
25
20
20
15
15
9
10
8
4
5
4
4
3
1
0
A61K
31/00
A61K
38/00
A61K
36/00
A61K
35/00
A61K
9/00
A61K
8/00
A61K
45/00
A61K
33/00
A61K
47/00
A61K
39/00
No. of Patent Families
IPC Class
14
15
10
7
8
5
5
3
3
1
1
1
2005
2006
2007
3
3
2
0
0
<2005
2008
2009
2010
2011
2012
2013
2014
2015
2016
Year
• For the IPC Class A61K, 2014 has maximum number of patent filing followed by 2013.
• Sub classes 31/00 (Medicinal preparations containing organic active ingredients) and
38/00 (Medicinal preparations containing peptides) have maximum focus.
© IIPRD, 2016
11
Priority Year based Filing Trend
140
119
120
97
No. of Patents
100
80
60
53
60
62
56
42
41
40
40
23
22
21
20
4
0
< 2005
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
Year
• 2010 was the priority year for maximum number of applications (119) followed by 2013
(97).
Note: For this graph, all family members were taken into consideration.
© IIPRD, 2016
12
Taxonomy
© IIPRD, 2016
13
Taxonomy
© IIPRD, 2016
14
Technical Data Analysis
© IIPRD, 2016
15
Product Form - Distribution
Other
10
Generic
32
Semisolid
5
Liquid Dosage
Form
Product Form
Confectionary/ Food Products
11
Suspensions/Emulsions
8
Beverages
27
Generic Liquids/ Solutions
30
Solid Dosage Form
Generic
6
Bar/ Biscuit/ Cookies
11
Capsules
16
Tablets
22
Powder/Granules
81
0
20
40
No. of Patent Families
60
80
100
Analysis of product forms indicates that maximum number of patents/published
applications included protein and amino acid based nutraceutical compositions in the form
of powders/granules (81), followed by liquids/solutions (30) and beverages (27).
Note: The data is mutually inclusive and hence the overall count maybe higher than the individual patent families.
© IIPRD, 2016
16
Product Form – Filing Trend
50
No. of Patent Families
45
40
35
30
25
20
15
10
5
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
Powder/Granules
1
2
0
0
1
2
6
5
6
11
45
2
Tablets
0
1
0
0
0
1
2
2
1
3
12
0
Beverages
0
1
0
1
2
2
2
2
2
2
13
0
Application Year
Analysis of filing trend of product forms indicates that maximum number of
patents/published applications containing powder/ granule, tablet and beverages based
nutraceutical compositions were filed in the year 2015 (~45, ~12, ~13 respectively),
followed by a dip in 2016 which maybe due to applications not published so far.
Note: The data is mutually inclusive and hence the overall count maybe higher than the individual patent families.
© IIPRD, 2016
17
Protein Ingredient - Distribution
40
37
29
30
27
25
12
15
14
10
10
14
11
10
9
5
18
15
6
7
7
Generic Protein
20
Microbial Protein
No. of Patent Families
35
2
1
Plant Based Protein
Milk Based Protein
Protein
other
generic
Gelatin
Egg
Collagen
Others
generic
Casein
Whey
Others
generic
Pea
Wheat
Rice
Soy
0
Animal based Protein
Analysis of protein ingredients indicates that maximum number of patents/published
applications included soy based nutraceutical compositions (37), closely followed by
Whey (27) and Collagen (18).
Note: The data is mutually inclusive and hence the overall count maybe higher than the individual patent families.
© IIPRD, 2016
18
Protein Ingredient – Filing Trend
25
No. of Patent Families
20
15
10
5
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
Soy
1
0
0
0
1
0
3
4
2
5
20
1
Whey
1
0
0
0
0
1
1
2
2
1
19
0
Collagen
0
0
0
0
0
0
0
0
1
2
15
0
Application Year
Analysis of filing trend of protein ingredients indicates that maximum number
patents/published applications containing soy, whey and collagen based nutraceutical
Composition were filed in the year 2015 (~20, ~19, ~15 respectively), followed by a dip in
2016 which maybe due to applications not published so far.
Note: The data is mutually inclusive and hence the overall count maybe higher than the individual patent families.
© IIPRD, 2016
19
Amino Acid - Distribution
Non- Essential
Arginine
11
Glutamine/Glutamic Acid
10
Cysteine
9
Essential
Amino Acid
Branch chain
Other
16
Leucine
13
Valine
7
Isoleucine
6
Methionine
11
Lysine
8
Phenylalanine
7
Other
14
0
2
4
6
8
10
12
14
16
18
No. of Patent Families
Analysis of amino acids indicates that maximum number of patents/published
applications included Leucine based nutraceutical compositions (13), closely followed by
Arginine (11) and Methionine (11).
Note: The data is mutually inclusive and hence the overall count maybe higher than the individual patent families.
© IIPRD, 2016
20
Target Population - Distribution
85
90
No. of Patent Families
80
70
60
50
40
30
26
23
20
11
10
8
7
6
3
0
Patient
Infant
Older
Person
Adult
Women
Sports
Generic
Others
Target
Analysis of target population indicates that maximum number of patents/published
applications included protein and amino acid based nutraceutical compositions directed
towards the treatment of specific patients (26), followed by infant formulas (23).
Note: The data is mutually inclusive and hence the overall count maybe higher than the individual patent families.
© IIPRD, 2016
21
Target Population – Filing Trend
14
No. of Patent Families
12
10
8
6
4
2
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
Infant
1
1
0
0
0
1
1
1
1
5
11
1
Patient
0
0
0
0
2
0
1
4
2
4
12
0
Application Year
Analysis of filing trend of target population indicates that maximum number
patents/published applications containing infant and patient based nutraceutical
compositions were filed in the year 2015 (~11, ~12 respectively), followed by a dip in 2016
which maybe due to applications not published so far.
Note: The data is mutually inclusive and hence the overall count maybe higher than the individual patent families.
© IIPRD, 2016
22
Application - Distribution
Analysis of applications (end-uses) indicates that maximum number of protein and amino
acid based nutraceutical composition containing patents/published applications were
directed towards the overall health benefit (58), followed by weight management (23) and
immunity enhancement (20).
Note: The data is mutually inclusive and hence the overall count maybe higher than the individual patent families.
© IIPRD, 2016
23
Application – Filing Trend
35
30
No. of Patent Families
25
20
15
10
5
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
Overall Health
1
1
0
1
1
1
2
3
5
7
33
3
Weight management
0
0
0
0
1
2
0
0
1
6
12
0
Immunity Enhancement
0
1
0
0
1
0
0
0
0
2
16
0
Application Year
Analysis of filing trend of applications (end-uses) indicates that maximum number of
patents/published applications containing protein and amino acid nutraceutical
composition directed towards the overall health benefit, weight management and
immunity enhancement containing were filed in the year 2015 (~33, ~12, ~16 respectively),
followed by a dip in 2016 which maybe due to applications not published so far.
Note: The data is mutually inclusive and hence the overall count maybe higher than the individual patent families.
© IIPRD, 2016
24
Competitor Analysis
© IIPRD, 2016
25
Top Assignees (1/2)
Abbott Laboratories
18
Assignees
Nestle S.A.
11
Qidong Xinyang Electronics Co. Ltd.
5
Qidong Wanying Electrical Factory
5
LKK Health Products Group
3
South China University of Technology
3
0
2
4
6
8
10
12
14
16
18
20
No. of Patent Families
Abbott Lab and Nestle were found to be top assignees with highest number of
innovations (individual patent families), significant patent filing in the technology
domain. Abbott leads the pack with highest number of filing (18 patent families),
followed by Nestle (11 Patent Families).
© IIPRD, 2016
26
Top Assignees (2/2)
Nestle S.A.
151
Abbott Laboratories
110
Northern Innovations Holding Corp.
33
Natural Alternatives International Inc.
29
Assignee
Cargill Inc
18
Ls2 Llc
14
Laboratoires Expanscience
13
Murray Goulburn Co-Operative Co Limited
12
Raisio Nutrition Ltd
11
Institut National De La Recherche Agronomique (Inra)
11
Puretein Bioscience Llc
10
Groupe Danone
10
0
50
100
150
200
No. of Patents
Abbott Lab and Nestle were found to be top assignees having 151 and 110 patent
publication filed worldwide. Interestingly, Nestle has less number of innovations
compared to Abbott but has sought much wider protection for the innovations.
Note: For this graph, all family members were taken into consideration.
© IIPRD, 2016
27
Assignee Filing Trend
12
No. of Patent Families
10
8
6
4
2
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
Abbott
1
0
0
0
0
0
4
1
1
0
11
0
Nestle
0
0
0
0
1
1
0
2
2
1
4
0
Application Year
In 2015, Abbott Lab and Nestle has maximum no. of patent applications, 11 and 4 patent
families respectively.
© IIPRD, 2016
28
Assignee Vs Protein
15
9
10
6
5
4
5
2
5
2
1
1
0
Soy
Pea
Rice
2
Wheat
2
1
3
2
1
Whey
Casein
Plant
Egg
Abbott
Assignee
No. of Patent Families
6
Nestle
Gelatin
Collagen
Milk
Microbial
Protein
Animal
Protein
• Abbott Lab has primary focus on the soy based protein (9 patent families) composition.
In many of Abbott’s products (Similac and RCF), soya protein is main protein source.
• Nestle has primarily focus on Whey based protein (5 patent families) compared to Soy
(2 patent families). Nestle’s product (Good Start) have whey based protein.
© IIPRD, 2016
29
Assignee Vs Product Form
4
2
1
1
2
Solid
1
2
Abbott
1
Nestle
Semisolid
Bar
Tablets
1
Confectionary
1
Suspensions/Emulsions
0
2
Assignee
3
2
5
Beverages
9
Capsules
10
Powder
No. of Patent Families
12
15
Liquid
Product Form
Both Abbott (12 patent families) and Nestle (9 patent Families) have primary focus on
the powder as product form. Advantages of powder is : (a) Powder is stable and does
not enter into reaction in solid state, (b) manufacturing of powder is economic, (C) less
incompatibility as compared to liquid dosage form and (D) protein nutraceutical
required in larger amount (in grams), conventional dosage of a supplement based
requirement of can easily dispensed.
© IIPRD, 2016
30
Assignee Vs Target
10
10
5
5
1
2
3
4
2
0
Infant
Sports
Patient
Target
Abbott
Nestle
women
Old Person
Assignee
No. of Patent Families
15
Adults
Abbott Lab has primary focus on infants (10 Patent families). Whereas, Nestle has
maximum patents targeting patients (5 patent families).
© IIPRD, 2016
31
15
10
10
3
5
0
3
1
4
2
1
2
1
Abbott
Assignee
No. of Patent Families
Assignee Vs Application
Nestle
Application
• Abbott Lab (10 Patent families) and Nestle (4 patent families) have primary focus on
overall health.
© IIPRD, 2016
32
White Space Analysis
© IIPRD, 2016
33
White Space Analysis - Protein Vs Target
© IIPRD, 2016
34
White Space Analysis - Protein Vs Application
© IIPRD, 2016
35
Market Analysis
© IIPRD, 2016
36
Market Data (1/2)
% breakdown of revenue for dietary ingredient
• Dietary supplements are products that are
specifically intended help meet recommended
dietary requirements and supplement regular diet.
The dietary supplement is multi-billion dollar
business. Market share for different ingredient is
presented in the figure left. Protein and amino acid
accounted for more than 55% revenue.1
• Global protein and amino acids market is estimated
to grow CAGR of more than 6% by 2020 2 and
projected revenue by 2022 is USD 40.8 billion. 1
For 2014, region wise market share of protein
Ingredients presented in image. The North American
region accounted for the largest share, owing to the
high consumption of protein-based products. The
global market in the Asia-Pacific region is emerging
with substantial opportunities.3
Protein Market Share by Region
© IIPRD, 2016
37
Market Data (2/2)
• Protein ingredients are essentially protein extracts from different sources such as plant
(soy, pea), animal (egg, collagen), milk (whey, casein), microorganism (spirulina) so on.
The demand for particular type of protein is dependent end user.
• Protein Ingredients market size in terms of volume1 and revenue2 is presented in the
following graphs. There is a paradigm shift in the protein market. plant protein
ingredients will dominate the protein ingredients market and is expected to grow at a
CAGR of more than 7% by 2020.3
4000
3500
Plant
9.2
2500
30.0
2000
1500
1000
500
0
Animal
40.0
Billion USD
Kilo Tons
3000
6.4
20.0
29.8
22.7
10.0
Animal
2014
2536
2015
2705
2016
2818
2017
2953
2018
3156
2019
3382
2020
3607
Plant
1815
1916
2029
2119
2198
2311
2480
Global protein type by volume
© IIPRD, 2016
0.0
2015
2020
Global protein type by Revenue
38
Mergers and Acquisitions
Acquirer
Acquiree
Highlight
Year
Source
Nestle
Pfizer
Nutrition
To strengthen position in global infant
nutrition market nestle acquired Pfizer
Nutrition.
2012
http://www.nestle.co
m/media/pressrelease
s/allpressreleases/pfize
r-nutrition-closing
Archer
Daniels
Midland
(ADM)
Harvest
Innovations
Archer Daniels Midland (ADM)
Enhances Plant Protein, Gluten-Free
Ingredient Portfolio with Purchase of
Harvest Innovations, an industry leader
in minimally processed, expellerpressed soy proteins, oils and glutenfree ingredients.
2016
http://www.adm.com/
news/_layouts/PressRe
leaseDetail.aspx?ID=70
6
Balchem
Corporati
on
Albion
International,
Inc.
Strategic expansion of human health
and wellness solutions portfolio
Balchem Corporation acquired Albion
International.
2016
http://www.balchem.c
om/balchemcorporation-acquiresalbion-internationalinc-1
© IIPRD, 2016
39
Recent News
© IIPRD, 2016
40
Disclaimer
© IIPRD, 2016
41
Disclaimer
The information provided in this report is based on database and
information sources that are believed to be reliable by the IIPRD. While
IIPRD has used the best resources for the commercial evaluation work,
IIPRD disclaims all warranties as to the accuracy, completeness or
adequacy of such information. The above report is prepared based on
the searches conducted on the keywords and other information
provided by the client. The comments provided are subject to results
identified up to the date of this report and subjectivity of the
researcher and analysts. Neither IIPRD nor its affiliates nor any of its
proprietors, employees (together, "personnel") are intending to
provide legal advice in this matter.
© IIPRD, 2016
42